Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hopkins

Showing results (291-300 of 883) with videos related to

Pageof 89
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLCMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Antisense & Nucleic Acid Drug Development|November 18, 2000
The influence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzymeM J Cairns, T M Hopkins, C Witherington, et al.
Analytical Biochemistry|April 29, 2004
Characterization of major histocompatibility complex-associated peptides from a small volume of whole bloodLeann M Hopkins, Michael Schall, Joseph F Leykam, et al.
Nature|March 28, 2009
The phantom menace of gene patentsSibylle Gaisser, Michael M Hopkins, Kathleen Liddell, et al.
Pigment Cell & Melanoma Research|February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial dataAshley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 15, 2017
Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen speciesCathy E Richards, Sri H Vellanki, Yvonne E Smith, et al.
Theriogenology|April 1, 1989
Farrowing induction with cloprostenol-xylazine combinationJ C Ko, L E Evans, W H Hsu, et al.
The Oncologist|April 29, 2021
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with AbemaciclibSarah Badaoui, Ganessan Kichenadasse, Andrew Rowland, et al.
Anaesthesia|February 19, 1999
Suxamethonium, masseter spasm and later malignant hyperthermiaJ A Ramirez, E D Cheetham, A S Laurence, et al.
Pageof 89

Showing results (291-300 of 883) with videos related to

Sort By:
Pageof 89
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLCMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Antisense & Nucleic Acid Drug Development|November 18, 2000
The influence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzymeM J Cairns, T M Hopkins, C Witherington, et al.
Analytical Biochemistry|April 29, 2004
Characterization of major histocompatibility complex-associated peptides from a small volume of whole bloodLeann M Hopkins, Michael Schall, Joseph F Leykam, et al.
Nature|March 28, 2009
The phantom menace of gene patentsSibylle Gaisser, Michael M Hopkins, Kathleen Liddell, et al.
Pigment Cell & Melanoma Research|February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial dataAshley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 15, 2017
Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen speciesCathy E Richards, Sri H Vellanki, Yvonne E Smith, et al.
Theriogenology|April 1, 1989
Farrowing induction with cloprostenol-xylazine combinationJ C Ko, L E Evans, W H Hsu, et al.
The Oncologist|April 29, 2021
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with AbemaciclibSarah Badaoui, Ganessan Kichenadasse, Andrew Rowland, et al.
Anaesthesia|February 19, 1999
Suxamethonium, masseter spasm and later malignant hyperthermiaJ A Ramirez, E D Cheetham, A S Laurence, et al.
Pageof 89